NVS: Novartis AG Stocks News on November 27, 2025

Why IBD 50's No. 3 Stock, Travere Therapeutics, Has Doubled In 2025

NVS

Investor's Business Daily

a day ago

Why IBD 50's No. 3 Stock, Travere Therapeutics, Has Doubled In 2025

Here's Why Novus Holdings (JSE:NVS) Has Caught The Eye Of Investors

NVS

Simply Wall St.

a day ago

Here's Why Novus Holdings (JSE:NVS) Has Caught The Eye Of Investors

Arrowhead Pharmaceuticals Inc (ARWR) Q4 2025 Earnings Call Highlights: FDA Approval and ...

NVS

GuruFocus.com

a day ago

Arrowhead Pharmaceuticals Inc (ARWR) Q4 2025 Earnings Call Highlights: FDA Approval and ...

Why Novartis Stock Topped the Market Today

NVS

Motley Fool

2 days ago

Why Novartis Stock Topped the Market Today

Novartis (SWX:NOVN): Evaluating Valuation as Shares Outperform with 17% Year-to-Date Return

NVS

Simply Wall St.

2 days ago

Novartis (SWX:NOVN): Evaluating Valuation as Shares Outperform with 17% Year-to-Date Return

Workday Announces Fiscal 2026 Third Quarter Financial Results

NVS

PR Newswire

2 days ago

Workday Announces Fiscal 2026 Third Quarter Financial Results

Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results

NVS

Business Wire

2 days ago

Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results

FDA Greenlights Novartis' Gene Replacement Treatment for SMA

NVS

Zacks

2 days ago

FDA Greenlights Novartis' Gene Replacement Treatment for SMA

NVS

MT Newswires

2 days ago

Sector Update: Health Care Stocks Edge Higher Premarket Tuesday

NVS

MT Newswires

2 days ago

Sector Update: Health Care

NVS

MT Newswires

2 days ago

Exchange-Traded Funds Higher, Equity Futures Lower Pre-Bell Tuesday Ahead of Delayed Data Releases

Novartis Canada Welcomes Dimitri Gitas as New Country President

NVS

CNW Group

2 days ago

Novartis Canada Welcomes Dimitri Gitas as New Country President

NVS

MT Newswires

2 days ago

Novartis Gets FDA Approval for Spinal Muscular Atrophy Treatment; Shares Rise Premarket

NVS

MT Newswires

2 days ago

Market Chatter: Novartis to Eliminate Up to 550 Roles at Stein Facility in Switzerland

NVS

Investing.com

2 days ago

BofA upgrades Novartis and GSK as pivotal data, new launches approach

Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS

NVS

GlobeNewswire

2 days ago

Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS

NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth

NVS

Zacks

6 days ago

NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth

Novartis to build manufacturing hub in North Carolina with $771M investment

NVS

Manufacturing Dive

6 days ago

Novartis to build manufacturing hub in North Carolina with $771M investment

Novartis Lifts Outlook With Stronger Peak Sales Forecasts

NVS

GuruFocus.com

6 days ago

Novartis Lifts Outlook With Stronger Peak Sales Forecasts

NVS

MT Newswires

7 days ago

European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading

Novartis Hikes Cancer Drug Targets--Signals Billions More in Pipeline Firepower

NVS

GuruFocus.com

7 days ago

Novartis Hikes Cancer Drug Targets--Signals Billions More in Pipeline Firepower

NVS

Financial Times

7 days ago

US healthcare group Abbott bets on cancer screening technology in $23bn deal

NVS

MT Newswires

7 days ago

Sector Update: Health Care Stocks Edge Higher Premarket Thursday

NVS

MT Newswires

7 days ago

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Jobs Data

Novartis taps North Carolina as new manufacturing hub location

NVS

Pharmaceutical Technology

7 days ago

Novartis taps North Carolina as new manufacturing hub location

NVS

The Wall Street Journal

7 days ago

Health Care Roundup: Market Talk

Novartis Expects Key Drugs, Recent Deals to Buoy Sales Into 2030s

NVS

The Wall Street Journal

7 days ago

Novartis Expects Key Drugs, Recent Deals to Buoy Sales Into 2030s

NVS

MT Newswires

7 days ago

Novartis Rolls Forward Mid-Term Sales Outlook to 2025-2030, Expects Over 5% to 6% Sales CAGR

Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets

NVS

GlobeNewswire

7 days ago

Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets

Morgan Stanley Upgrades Novartis (NVS) to Overweight, Raises Price Target to CHF 110

NVS

Insider Monkey

8 days ago

Morgan Stanley Upgrades Novartis (NVS) to Overweight, Raises Price Target to CHF 110

Inherited Retinal Disease Market Analysis Report 2025-2035, Featuring Profiles of Novartis, GenSight Biologics, Aldeyra Therapeutics, and Spark Therapeutics

NVS

GlobeNewswire

8 days ago

Inherited Retinal Disease Market Analysis Report 2025-2035, Featuring Profiles of Novartis, GenSight Biologics, Aldeyra Therapeutics, and Spark Therapeutics

Portal Hypertension Drugs Market Research Report 2025-2035: Key Dynamics, Pipeline Analysis, Regulatory Landscape, Epidemiology

NVS

GlobeNewswire

8 days ago

Portal Hypertension Drugs Market Research Report 2025-2035: Key Dynamics, Pipeline Analysis, Regulatory Landscape, Epidemiology

Intestinal Fistula Market Analysis Report 2025-2035: Competition Intensifies as Sanofi and Novartis Drive Innovation Through Strategic Partnerships and Advanced Treatment Expansion

NVS

GlobeNewswire

9 days ago

Intestinal Fistula Market Analysis Report 2025-2035: Competition Intensifies as Sanofi and Novartis Drive Innovation Through Strategic Partnerships and Advanced Treatment Expansion

Microscopic Polyangiitis Market Research Report 2025-2035, Competitive Analysis of Roche, Amgen, Teva, Novartis, Baxter, Amerigen Pharma, InflaRx, Biogen, Pfizer, Celltrion

NVS

GlobeNewswire

9 days ago

Microscopic Polyangiitis Market Research Report 2025-2035, Competitive Analysis of Roche, Amgen, Teva, Novartis, Baxter, Amerigen Pharma, InflaRx, Biogen, Pfizer, Celltrion

Here's Why Novartis (NVS) is a Strong Value Stock

NVS

Zacks

13 days ago

Here's Why Novartis (NVS) is a Strong Value Stock

Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint

NVS

Zacks

14 days ago

Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint

Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance

NVS

GlobeNewswire

15 days ago

Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance

First New Malaria Drug in Years Performs Strongly in Late-Stage Testing

NVS

The Wall Street Journal

15 days ago

First New Malaria Drug in Years Performs Strongly in Late-Stage Testing

NVS

MT Newswires

17 days ago

Sector Update: Health Care Stocks Advance Late Afternoon

NVS

MT Newswires

17 days ago

Sector Update: Health Care Stocks Advance Monday Afternoon

Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan

NVS

GlobeNewswire

17 days ago

Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan

More Drugs to Fight High Cholesterol Are Emerging

NVS

The Wall Street Journal

19 days ago

More Drugs to Fight High Cholesterol Are Emerging

This Unlikely Duo Is Developing a Weight-Loss Pill. Big Pharma Is Obsessed.

NVS

The Wall Street Journal

19 days ago

This Unlikely Duo Is Developing a Weight-Loss Pill. Big Pharma Is Obsessed.

Needle-Free Devices, Technologies and Global Markets (2025-2030) Featuring Profiles of GSK, Novartis, Viatris, PharmaJet and Other Key Players

NVS

GlobeNewswire

21 days ago

Needle-Free Devices, Technologies and Global Markets (2025-2030) Featuring Profiles of GSK, Novartis, Viatris, PharmaJet and Other Key Players

Chronic Heart Failure Market Analysis and Forecast, 2025-2035, Featuring AstraZeneca, Bristol Myers Squibb, Cytokinetics, Bayer, Eli Lilly and Other Leading Players

NVS

GlobeNewswire

21 days ago

Chronic Heart Failure Market Analysis and Forecast, 2025-2035, Featuring AstraZeneca, Bristol Myers Squibb, Cytokinetics, Bayer, Eli Lilly and Other Leading Players

Celcuity Eyeing Cancer Treatment Riddle. Stock Flies 534% This Year.

NVS

Investor's Business Daily

21 days ago

Celcuity Eyeing Cancer Treatment Riddle. Stock Flies 534% This Year.

Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates

NVS

GlobeNewswire

21 days ago

Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates

Nucleic Acid Therapeutics Market Report 2025: Competition Intensifies as Pfizer, Sanofi, Novartis, Moderna, BioNTech Expand Antisense and RNA Platform Innovations - Long-term Forecast to 2029 & 2034

NVS

GlobeNewswire

22 days ago

Nucleic Acid Therapeutics Market Report 2025: Competition Intensifies as Pfizer, Sanofi, Novartis, Moderna, BioNTech Expand Antisense and RNA Platform Innovations - Long-term Forecast to 2029 & 2034

New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline

NVS

GlobeNewswire

23 days ago

New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline

Solid Earnings Reflect Novartis' (VTX:NOVN) Strength As A Business

NVS

Simply Wall St.

24 days ago

Solid Earnings Reflect Novartis' (VTX:NOVN) Strength As A Business

NVS

Morningstar Research

24 days ago

Analyst Report: Incyte Corporation

NVS

Business Wire

24 days ago

Meharry and Novartis Partner on HEART Initiative for Healthier Communities

United States Multiple Myeloma Market Research Report 2025-2033, Profiles of Key Players - Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, Takeda, and Bristol-Myers Squibb

NVS

GlobeNewswire

24 days ago

United States Multiple Myeloma Market Research Report 2025-2033, Profiles of Key Players - Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, Takeda, and Bristol-Myers Squibb

Avidity Biosciences (RNA) Soars 42% on $12-Billion Novartis Merger

NVS

Insider Monkey

24 days ago

Avidity Biosciences (RNA) Soars 42% on $12-Billion Novartis Merger

Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think)

NVS

Motley Fool

a month ago

Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think)

NVS

Morningstar Research

a month ago

Analyst Report: Intellia Therapeutics, Inc.

NVS

Morningstar Research

a month ago

Analyst Report: Haleon plc

Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook

NVS

Zacks

a month ago

Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook

NVS

Morningstar Research

a month ago

Analyst Report: Incyte Corporation

Breckenridge announces launch of Everolimus Tablets, 1mg, generic version of Zortress®

NVS

PR Newswire

a month ago

Breckenridge announces launch of Everolimus Tablets, 1mg, generic version of Zortress®

Novartis (SWX:NOVN) Earnings Jump 22%—Profit Beat Reinforces Margin and Value Narratives

NVS

Simply Wall St.

a month ago

Novartis (SWX:NOVN) Earnings Jump 22%—Profit Beat Reinforces Margin and Value Narratives

NVS

MT Newswires

a month ago

Novartis Says Ianalumab Showed Reduced Disease Activity in Phase III Trials for Sjogren's Disease

Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials

NVS

GlobeNewswire

a month ago

Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials

Why Novartis (NVS) is a Top Value Stock for the Long-Term

NVS

Zacks

a month ago

Why Novartis (NVS) is a Top Value Stock for the Long-Term

What's the Driving Force Behind Eli Lilly's Recent Acquisition Spree?

NVS

Zacks

a month ago

What's the Driving Force Behind Eli Lilly's Recent Acquisition Spree?

NVS

Morningstar Research

a month ago

Analyst Report: Novartis AG

CAR T-cell Therapy Market Forecasts Indicate Strong Growth Trajectory in the 7MM During the Forecast Period (2025-2034) | DelveInsight

NVS

PR Newswire

a month ago

CAR T-cell Therapy Market Forecasts Indicate Strong Growth Trajectory in the 7MM During the Forecast Period (2025-2034) | DelveInsight

Novartis Slips As Generics Bite Into Its Heart-Failure Drug Sales In Mixed Third Quarter

NVS

Investor's Business Daily

a month ago

Novartis Slips As Generics Bite Into Its Heart-Failure Drug Sales In Mixed Third Quarter

Novartis Profit Rises on Cancer Drug Momentum

NVS

GuruFocus.com

a month ago

Novartis Profit Rises on Cancer Drug Momentum

NVS

The Wall Street Journal

a month ago

Health Care Roundup: Market Talk

INCY's Q3 Earnings & Revenues Beat Estimates on Higher Product Sales

NVS

Zacks

a month ago

INCY's Q3 Earnings & Revenues Beat Estimates on Higher Product Sales

Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition

NVS

Zacks

a month ago

Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition

Novartis completes acquisition of Tourmaline Bio

NVS

GlobeNewswire

a month ago

Novartis completes acquisition of Tourmaline Bio

Warner Bros. Discovery upgraded, F5 downgraded: Wall Street's top analyst calls

NVS

The Fly

a month ago

Warner Bros. Discovery upgraded, F5 downgraded: Wall Street's top analyst calls

Why Dyne Therapeutics Stock Crushed the Market on Monday

NVS

Motley Fool

a month ago

Why Dyne Therapeutics Stock Crushed the Market on Monday

Why Avidity Biosciences Stock Blasted 42% Higher Today

NVS

Motley Fool

a month ago

Why Avidity Biosciences Stock Blasted 42% Higher Today

NVS

The Wall Street Journal

a month ago

Health Care Roundup: Market Talk

Stocks to Watch Monday: Amazon, Nvidia, Novartis, Keurig Dr Pepper

NVS

The Wall Street Journal

a month ago

Stocks to Watch Monday: Amazon, Nvidia, Novartis, Keurig Dr Pepper

These Stocks Are Moving the Most Today: Qualcomm, MP Materials, USA Rare Earth, Tesla, Avidity, Newmont, Microsoft, and More

NVS

Barrons.com

a month ago

These Stocks Are Moving the Most Today: Qualcomm, MP Materials, USA Rare Earth, Tesla, Avidity, Newmont, Microsoft, and More

NVS

MT Newswires

a month ago

Sector Update: Health Care Stocks Increase Late Afternoon

Novartis To Buy Avidity Biosciences In $12 Billion Rare-Disease Deal

NVS

GuruFocus.com

a month ago

Novartis To Buy Avidity Biosciences In $12 Billion Rare-Disease Deal

NVS

MT Newswires

a month ago

Top Midday Gainers

Jim Cramer Says He is a “Buyer of Novartis”

NVS

Insider Monkey

a month ago

Jim Cramer Says He is a “Buyer of Novartis”

Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases

NVS

GlobeNewswire

a month ago

Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases

Novartis (SWX:NOVN): Exploring Valuation Perspectives as Shares Gain 12% Over Three Months

NVS

Simply Wall St.

a month ago

Novartis (SWX:NOVN): Exploring Valuation Perspectives as Shares Gain 12% Over Three Months

Fed Rate Move, Apple Earnings, Trump-Xi Meeting: What to Watch Next Week

NVS

The Wall Street Journal

a month ago

Fed Rate Move, Apple Earnings, Trump-Xi Meeting: What to Watch Next Week

Will Biogen Beat on Q3 Earnings? Leqembi, Skyclarys Could Hold the Key

NVS

Zacks

a month ago

Will Biogen Beat on Q3 Earnings? Leqembi, Skyclarys Could Hold the Key

Incyte Gears Up to Report Q3 Earnings: Is a Beat in the Cards?

NVS

Zacks

a month ago

Incyte Gears Up to Report Q3 Earnings: Is a Beat in the Cards?

REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?

NVS

Zacks

a month ago

REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?

Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast Period (2025-2034) Driven by Rising Diagnostics and Immuno-Oncology Advances | DelveInsight

NVS

PR Newswire

a month ago

Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast Period (2025-2034) Driven by Rising Diagnostics and Immuno-Oncology Advances | DelveInsight

Gear Up for Novartis (NVS) Q3 Earnings: Wall Street Estimates for Key Metrics

NVS

Zacks

a month ago

Gear Up for Novartis (NVS) Q3 Earnings: Wall Street Estimates for Key Metrics

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

NVS

Zacks

a month ago

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

United States Chronic Obstructive Pulmonary Disease Market Report 2025-2033, Profiles of AstraZeneca, Pfizer, GSK, Novartis, Astellas Pharma, Abbott Laboratories, Boehringer Ingelheim, Almirall

NVS

GlobeNewswire

a month ago

United States Chronic Obstructive Pulmonary Disease Market Report 2025-2033, Profiles of AstraZeneca, Pfizer, GSK, Novartis, Astellas Pharma, Abbott Laboratories, Boehringer Ingelheim, Almirall

Glomerulonephritis Market Projected to Surge by 2034 with Rising Demand for Targeted Therapies | DelveInsight

NVS

PR Newswire

a month ago

Glomerulonephritis Market Projected to Surge by 2034 with Rising Demand for Targeted Therapies | DelveInsight

Novartis (NVS) is an Incredible Growth Stock: 3 Reasons Why

NVS

Zacks

a month ago

Novartis (NVS) is an Incredible Growth Stock: 3 Reasons Why

Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings

NVS

Zacks

a month ago

Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings

Is There Still Upside in Novartis After Hitting a New 2025 Share Price High?

NVS

Simply Wall St.

a month ago

Is There Still Upside in Novartis After Hitting a New 2025 Share Price High?

Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)

NVS

GlobeNewswire

a month ago

Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)

Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer

NVS

GlobeNewswire

a month ago

Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer

NVS

MT Newswires

a month ago

Latest Novartis AG (NVS) News on November 27, 2025

Share on Social Networks: